Annual meeting moves to the New York Marriott Marquis on October 13-16, marking a new chapter and providing a refreshed ...

Ameet Patel, MD, concludes by outlining strategies to overcome operational, financial, and payer challenges in delivering advanced multiple myeloma therapies.

A myeloma survivor in long remission shares how research, expert care and advocacy turned fear into hope as more patients ...

Jaime Suarez-Londono, MD: Transplant for myeloma is very easy to give. On day 12 they engraft and they go home. Adverse events are not that [severe], and they get this progression-free survival [PFS] ...

Ameet Patel, MD, explains how multiple myeloma treatment settings depend on safety, logistics, and patient needs.

Iberdomide has the potential to be the first approved CELMoD agentThe U.S. FDA has granted Breakthrough Therapy Designation and Priority Review for this indication and assigned a target action date of ...

After a broken femur led to a multiple myeloma diagnosis, one patient is raising awareness while specialists point to new treatment options and early detection.

Phase 3 trial results suggest daratumumab, which is approved for multiple myeloma, may also be effective at reducing relapse risk in neuromyelitis optica spectrum disorder.

At Beth Israel Deaconess Medical Center, doctors say a once-fringe treatment for multiple myeloma is starting to look like a legitimate frontline weapon for some patients. CAR T cell therapy is ...

Doctors at Boston’s Beth Israel share how CAR T cell therapy and other emerging immune therapies are delivering promising ...

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q4 2025 Earnings Call Transcript February 12, 2026 Karyopharm Therapeutics Inc.

Colleen Mabasa, a patient with multiple myeloma, sat down with CURE for an interview to discuss how she pursued chimeric antigen receptor (CAR)-T cell therapy, navigated insurance and logistical ...